Title: Efficacy and safety of subanesthetic doses of esketamine combined with propofol in
painless gastrointestinal endoscopy: a prospective, double-blind, randomized controlled trial
Version: 2 Date: 03 Jun 2022
Reviewer's report:
1.       In the abstract's results, this sentence should be deleted " Data from 260 patients were
analyzed.".
2.       In the introduction section, some sentences about pain and its mechanism should be
discussed. these references are strongly advised to be cited:
-          Skovlund, Eva, et al. "Sensitivity of pain rating scales in an endoscopy trial." The Clinical
journal of pain 21.4 (2005): 292-296.
-          Maghbool, Maryam, et al. "The effects of eugenol nanoemulsion on pain caused
by arteriovenous fistula cannulation in hemodialysis patients: a randomized double-blinded
controlled cross-over trial." Complementary therapies in medicine 52 (2020): 102440.
3.       The CONSORT flowchart, the label of analysis stage is incorrect (allocation).
4.       In table 1, what was your aim for the mentioning co-morbidities? Also, there is a typo
[0(1.5%)].
5.       In Table 5, I do not think that p-value for the first 4 rows is 1. Please recalculate it.
Title: Efficacy and safety of subanesthetic doses of esketamine combined with propofol in
painless gastrointestinal endoscopy: a prospective, double-blind, randomized controlled trial
Version: 2 Date: 03 Jun 2022
Reviewer's report:
1.       In the abstract's results, this sentence should be deleted " Data from 260 patients were
analyzed.".
2.       In the introduction section, some sentences about pain and its mechanism should be
discussed. these references are strongly advised to be cited:
-          Skovlund, Eva, et al. "Sensitivity of pain rating scales in an endoscopy trial." The Clinical
journal of pain 21.4 (2005): 292-296.
-          Maghbool, Maryam, et al. "The effects of eugenol nanoemulsion on pain caused
by arteriovenous fistula cannulation in hemodialysis patients: a randomized double-blinded
controlled cross-over trial." Complementary therapies in medicine 52 (2020): 102440.
3.       The CONSORT flowchart, the label of analysis stage is incorrect (allocation).
4.       In table 1, what was your aim for the mentioning co-morbidities? Also, there is a typo
[0(1.5%)].
5.       In Table 5, I do not think that p-value for the first 4 rows is 1. Please recalculate it.
Please review this paper.
user
Title: Efficacy and safety of subanesthetic doses of esketamine combined with propofol in
painless gastrointestinal endoscopy: a prospective, double-blind, randomized controlled trial
Version: 2 Date: 03 Jun 2022
Reviewer's report:
1.       In the abstract's results, this sentence should be deleted " Data from 260 patients were
analyzed.".
2.       In the introduction section, some sentences about pain and its mechanism should be
discussed. these references are strongly advised to be cited:
-          Skovlund, Eva, et al. "Sensitivity of pain rating scales in an endoscopy trial." The Clinical
journal of pain 21.4 (2005): 292-296.
-          Maghbool, Maryam, et al. "The effects of eugenol nanoemulsion on pain caused
by arteriovenous fistula cannulation in hemodialysis patients: a randomized double-blinded
controlled cross-over trial." Complementary therapies in medicine 52 (2020): 102440.
3.       The CONSORT flowchart, the label of analysis stage is incorrect (allocation).
4.       In table 1, what was your aim for the mentioning co-morbidities? Also, there is a typo
[0(1.5%)].
5.       In Table 5, I do not think that p-value for the first 4 rows is 1. Please recalculate it.
assistant